[go: up one dir, main page]

WO2010039529A3 - Compositions et méthodes destinées au traitement de maladies inflammatoires - Google Patents

Compositions et méthodes destinées au traitement de maladies inflammatoires Download PDF

Info

Publication number
WO2010039529A3
WO2010039529A3 PCT/US2009/058016 US2009058016W WO2010039529A3 WO 2010039529 A3 WO2010039529 A3 WO 2010039529A3 US 2009058016 W US2009058016 W US 2009058016W WO 2010039529 A3 WO2010039529 A3 WO 2010039529A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
agonist
formulae
inflammatory disease
sirtuin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/058016
Other languages
English (en)
Other versions
WO2010039529A2 (fr
Inventor
Per Gjorstrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resolvyx Pharmaceuticals Inc
Original Assignee
Resolvyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolvyx Pharmaceuticals Inc filed Critical Resolvyx Pharmaceuticals Inc
Priority to US13/120,493 priority Critical patent/US20110190242A1/en
Publication of WO2010039529A2 publication Critical patent/WO2010039529A2/fr
Publication of WO2010039529A3 publication Critical patent/WO2010039529A3/fr
Anticipated expiration legal-status Critical
Priority to US13/959,337 priority patent/US20130316989A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des méthodes permettant de traiter une maladie inflammatoire qui consistent à administrer un composé de formule A, un composé quelconque parmi ceux ayant la formule 1-49 ou I-III, un composé lipoxine ou un composé oxylipine.
PCT/US2009/058016 2008-09-23 2009-09-23 Compositions et méthodes destinées au traitement de maladies inflammatoires Ceased WO2010039529A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/120,493 US20110190242A1 (en) 2008-09-23 2009-09-23 Compositions and methods for the treatment of inflammatory disease
US13/959,337 US20130316989A1 (en) 2008-09-23 2013-08-05 Compositions and methods for the treatment of inflammatory disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19406608P 2008-09-23 2008-09-23
US61/194,066 2008-09-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/959,337 Continuation US20130316989A1 (en) 2008-09-23 2013-08-05 Compositions and methods for the treatment of inflammatory disease

Publications (2)

Publication Number Publication Date
WO2010039529A2 WO2010039529A2 (fr) 2010-04-08
WO2010039529A3 true WO2010039529A3 (fr) 2010-05-27

Family

ID=42074110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/058016 Ceased WO2010039529A2 (fr) 2008-09-23 2009-09-23 Compositions et méthodes destinées au traitement de maladies inflammatoires

Country Status (2)

Country Link
US (2) US20110190242A1 (fr)
WO (1) WO2010039529A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101901741B1 (ko) 2010-09-07 2018-10-01 서울대학교산학협력단 세스터터핀 화합물 및 이들 물질의 용도
BR112014013667A2 (pt) 2011-12-06 2017-06-13 Unilever Nv composição antienvelhecimento da pele
US20130158077A1 (en) * 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
WO2013192097A1 (fr) * 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Préparation, utilisations et formes solides d'acide obéticholique
WO2014039964A2 (fr) 2012-09-10 2014-03-13 The Regents Of The University Of California Composés et méthodes de modulation de blessures vasculaires
CN116440112A (zh) * 2014-01-24 2023-07-18 国立大学法人京都大学 含有稀有脂肪酸的抗炎剂
EP3097911B8 (fr) * 2014-01-24 2024-07-10 Noster Inc. Agent améliorant le métabolisme comprenant un acide gras rare
US20170326094A1 (en) * 2014-12-09 2017-11-16 Nestec S.A. Uses of bioactive lipids
US11690824B2 (en) 2018-04-10 2023-07-04 The General Hospital Corporation Antibacterial compounds
CA3116858A1 (fr) * 2018-10-16 2020-04-23 Systamedic Inc. Nouvelles compositions pour le traitement de maladies inflammatoires
CN114369022B (zh) * 2021-06-09 2022-11-11 辽宁中医药大学 马齿苋中一种有机酸类化合物及其提取分离方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236423A1 (en) * 2002-04-01 2003-12-25 Petasis Nicos A. Trihydroxy polyunsaturated eicosanoids
US6670396B2 (en) * 2000-02-16 2003-12-30 Brigham And Women's Hospital Aspirin-triggered lipid mediators
US20050228047A1 (en) * 2002-04-01 2005-10-13 Petasis Nicos A Trihydroxy polyunsaturated eicosanoid derivatives
US20050238589A1 (en) * 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
WO2008070129A2 (fr) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions et procédés pour le traitement de maladie inflammatoire

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670396B2 (en) * 2000-02-16 2003-12-30 Brigham And Women's Hospital Aspirin-triggered lipid mediators
US20030236423A1 (en) * 2002-04-01 2003-12-25 Petasis Nicos A. Trihydroxy polyunsaturated eicosanoids
US20050228047A1 (en) * 2002-04-01 2005-10-13 Petasis Nicos A Trihydroxy polyunsaturated eicosanoid derivatives
US20050238589A1 (en) * 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
WO2008070129A2 (fr) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions et procédés pour le traitement de maladie inflammatoire

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DECIUCEIS, C. ET AL.: "Synergistic vascular protective effects of combined low doses of PPARa and PPARy activators in angiotensin II-induced hypertension in rats", BRITISH J. PHARMACOLOGY, vol. 151, 2007, pages 45 - 53 *
KAPADIA, R. ET AL.: "Mechanisms. ofariti-inflammatory and neuroprotective actions of PPAR-gamma agonists", FRONT BIOSCI., vol. 13, January 2008 (2008-01-01), pages 1813 - 1826 *
WANG, K. ET AL.: "Nuclear Receptors and Inflammatory Diseases", EXP. BIOL. MED., vol. 233, no. 5, May 2008 (2008-05-01), pages 496 - 506 *

Also Published As

Publication number Publication date
US20110190242A1 (en) 2011-08-04
WO2010039529A2 (fr) 2010-04-08
US20130316989A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
WO2010039529A3 (fr) Compositions et méthodes destinées au traitement de maladies inflammatoires
CL2007002658A1 (es) Compuestos derivados de purina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
AR059575A1 (es) Metodo para el tratamiento de enfermedades inflamatorias
CY1115751T1 (el) Φαρμακευτικος συνδυασμος 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλπροπυλ)-φαινολης και ενος αντιεπιληπτικου
CY1116548T1 (el) Χρηση παραγωγων 1,3-διφαινυλπροπ-2-εν-1-ονης για την αγωγη ηπατικων διαταραχων
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
NO20083561L (no) Forbindelser for behandling av inflammatoriske forstyrrelser
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
WO2008122965A3 (fr) Compositions pharmaceutiques à base de cyclosporine
CY1117118T1 (el) Φαρμακευτικος συνδυασμος για την αγωγη του πονου
ATE460401T1 (de) 1,2,4,5-tetrahydro-3h-benzazepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
MA31706B1 (fr) Formulations galéniques de composés organiques
NI200800227A (es) Acidos 1,3-dioxano carboxilicos
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
ECSP11011286A (es) Formulaciones orales sólidas de una pirido-pirimidinona
CY1116601T1 (el) Φαρμακευτικη συνθεση που βασιζεται σε ηπατοπροστατευτικο παραγοντα και πρεβιοτικο, η παραγωγη και χρηση της
CO2017005201A2 (es) Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona
CL2008000554A1 (es) Compuestos derivados de diaminopirimidina sustituida; metodo de preparacion de dichos compuestos; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario, un estado patologico doloroso, un trastorno res
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
CL2011000520A1 (es) Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos.
BRPI0517065A (pt) derivado de ácido carboxìlico que contém anel de tiazol e uso farmacêutico deste
WO2018071315A3 (fr) Dérivés de pipéridine utilisés comme agonistes du récepteur nucléaire des oxystérols bêta, compositions et leur utilisation
FR2900823B1 (fr) Nouvelle forme d'administration du racecadotril.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09818270

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13120493

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09818270

Country of ref document: EP

Kind code of ref document: A2